⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718531 | 1.00 | — | — | |
| SCHEMBL718532 | 1.00 | — | — | |
| Water SCHEMBL28328238 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2723572 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL21065373 | 0.97 | MME (0.41) | — | |
| Hydrochloric Acid SCHEMBL1458134 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL1458136 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL21065375 | 0.97 | MME (0.41) | — | |
| SCHEMBL28925035 | 0.91 | MME (0.37) | — | |
| Trifluoroacetic Acid SCHEMBL3650862 | 0.87 | MME (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101180029-B | Parakeratosis inhibitor, pore-shrinking agent or agent for preventing and improving rough skin, and composition for external use on skin | SHISEIDO CO LTD | 2011-02-16 | — | — | CN | claimed |
| EP-1773877-B1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | claimed |
| EP-1976873-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-10-08 | — | — | EP | claimed |
| CN-101180029-A | Parakeratosis inhibitor, pore-shrinking agent or agent for preventing and improving rough skin, and composition for external use on skin | SHISEIDO CO LTD (JP) | 2008-05-14 | — | — | CN | claimed |
| EP-1884230-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | claimed |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | claimed |
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | Illudent, Inc. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-12269793-B2 | Affinity illudofulvene conjugates | AF CHEMICALS, LLC (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4257186-B1 | AFFINITY MEDICANT CONJUGATES | AF CHEMICALS LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-115466189-B | Purification method of amino acid and derivative thereof | 安徽普利药业有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-1908454-A1 | WRINKLE-PREVENTIVE/AMELIORATING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2008-04-09 | — | — | EP | disclosed |
| EP-1884230-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| CN-101010339-A | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2007-08-01 | — | — | CN | disclosed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |